ASH Conference San Diego 2023

Live in San Diego
Free CME Credits

Exciting Hematology Satellite Symposia Preceding the 65th ASH Annual Meeting and Exposition

Embark on an exciting journey into the world of hematology breakthroughs! Join us on Friday, Dec 8th, in sunny San Diego for 6 educational events unveiling the latest hematologic advancements. Engage with experts and other healthcare professionals, and gain practical insights into hematologic malignancies.

The best part? No ASH registration needed! All sessions are free, accredited for CME/CE, and include delicious refreshments. Last year's events were standing-room only – secure your seat today!

Date Friday, December 8, 2023

Time 6 Exciting Events
From 7:00 AM to 5:30 PM PT
Timezone Converter ›

Location Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101


Join us and your peers in-person this December!

7:00 AM PT
Morning Session (Breakfast Included)

Discussion Includes:

  • NCCN guidelines review for first-line and second-line regimens
  • Key variables in deciding between regimens
  • Mastering the current regimen components
    • Including MOA, key efficacy and safety data, and other considerations with BTK inhibitors, BCL-2 inhibitors, and anti-CD20 mAbs
  • Case discussions: putting it all together for effective management of CLL
  • On the horizon: MRD, CAR T-cell therapy, and noncovalent BTK inhibitors
  • ASH 2023 CLL abstract highlight: review of key studies to be presented at ASH


  • Danielle Brander, MD
  • Deborah Stephens, DO
  • Brian Hill, MD, PhD

Room Name:

  • Pacific Ballroom 21-22

11:00 AM PT
Morning Sessions (Lunch Included)

Discussion Includes:

  • Quiz and discussion 1: Changes to the MCL Treatment Landscape
    • Current treatment algorithm
    • Role of BTKis
    • Unmet clinical needs
  • Quiz and discussion 2: Current/Emerging Roles of BTKis in Untreated MCL
    • Mechanisms, PK/PD, and efficacy of BTKis
    • BTKis in transplant-eligible patients
    • Improving on BR in first-line MCL without transplant
  • Quiz and discussion 3: Selecting and Sequencing BTKis in R/R MCL
    • Resistance and intolerance to covalent BTKis
    • Treatment options and sequencing after BR plus BTKi
  • Panel discussions: New Data on Current Clinical Challenges
    • Combining and sequencing of novel agents
    • Overcoming barriers to and challenges with BTKi therapy
    • Key abstracts at SOHO 2023 and ASH 2023
  • Closing Remarks, Audience Question and Answer Session


  • Ann LaCasce, MD, MMSc
  • John P. Leonard, MD
  • Matthew Lunning, DO, FACP

Room Name:

  • Pacific Ballroom 21-22

Discussion Includes:

  • Partnering with Patients to Improve Outcomes and Quality of Life
  • Selecting Initial Treatment for Patients with Myelofibrosis
  • Recognizing Patterns of Suboptimal Response to First Line Myelofibrosis Treatment
  • Disease Progression or Intolerance to Initial Therapy
  • What's on the Horizon in Myelofibrosis Treatment


  • Jean-Jacques Kiladjian, MD, PhD
  • Abdulraheem Yacoub, MD

Room Name:

  • San Diego Ballroom AB

3:00 PM PT
Afternoon Sessions (Refreshments Included)

Discussion Includes:

  • Biology, clinical presentation, and diagnostic approach for AL amyloidosis
  • Overview of recent treatment guidelines
  • Current/evolving management algorithm for patients with newly diagnosed AL amyloidosis
  • Current/evolving algorithm for the management of AL amyloidosis at relapse
  • Clinical trial spotlight and review of key abstracts to be presented at ASH 2023


  • Angela Dispenzieri, MD
  • Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Room Name:

  • Pacific Ballroom 21-22

Discussion Includes:

  • Welcome, Introduction, and Baseline Assessment
  • Pathophysiology and Classification of CAD
    • Diagnostic criteria and current challenges
  • Current Data in the Therapeutic Management of CAD
    • CAD mechanism of action
    • Historical management
    • Targeted therapies: complement pathway inhibition
  • Future Directions
    • Novel agents in development
    • Clinical trial spotlight: key abstracts from ASH
  • Final Thoughts and Audience Question and Answer Session


  • Catherine M. Broome, MD
  • David Dingli, MD, PhD
  • Deva Sharma, MD, MS

Room Name:

  • San Diego Ballroom AB

Discussion Includes:

  • Welcome and Introduction
  • Overview of R/R FL and Unmet Needs
  • Patient Selection and Sequencing of New and Emerging Options For R/R FL
    • Bispecific Antibodies
    • Epigenetic Modifiers
    • PI3K Inhibitors
    • CAR T-Cell Therapy
  • Future Directions in R/R FL
  • Audience Question and Answer Session


  • Peter Martin, MD
  • Sonali Smith, MD, FASCO
  • Julie Vose, MD

Room Name:

  • Pacific Ballroom 18-19

Featured Faculty


Danielle Brander, MD

  • Assistant Professor of Medicine
  • Division of Hematologic Malignancies & Cellular Therapy
  • Department of Medicine
  • Duke University
  • Attending Physician, Hematologic Malignancies
  • Duke University Health System
  • Durham, North Carolina

Deborah Stephens, DO

  • Associate Professor
  • Director of the CLL Program
  • Lineberger Comprehensive Cancer Center
  • University of North Carolina
  • Chapel Hill, North Carolina

Brian Hill, MD, PhD

  • Director, Lymphoid Malignancies Program
  • Staff Physician, Department of Hematology and Medical Oncology
  • Taussig Cancer Institute
  • Cleveland Clinic
  • Cleveland, Ohio

Ann LaCasce, MD, MMSc

  • Associate Professor of Medicine
  • Lymphoma Program
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts

John P. Leonard, MD

  • Senior Associate Dean for Innovation and Initiatives
  • Chair (Interim), Weill Department of Medicine
  • Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
  • Weill Cornell Medicine/NewYork-Presbyterian
  • New York, New York

Matthew Lunning, DO, FACP

  • Associate Professor
  • Fred & Pamela Buffett Cancer Center
  • University of Nebraska Medical Center
  • Omaha, Nebraska

Jean-Jacques Kiladjian, MD, PhD

  • Professor
  • Department of Clinical Pharmacology
  • Université de Paris
  • Professor
  • Clinical Investigations Center
  • Saint-Louis Hospital
  • Paris, France

Abdulraheem Yacoub, MD

  • Professor of Medicine
  • The University of Kansas Cancer Center
  • Kansas City, Kansas

Angela Dispenzieri, MD

  • Consultant
  • Division of Hematology
  • Serene M. and Frances C. Durling
  • Professor of Medicine and of Laboratory Medicine
  • Mayo Clinic
  • Rochester, Minnesota

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

  • Professor of Medicine and Haematology
  • University College London
  • Honorary Consultant Haemetologist
  • University College Hospitals
  • Director, Jack O'Neil Laboratory
  • Department of Haematology
  • National Amyloidosis Centre
  • London, United Kingdom

Catherine M. Broome, MD

  • Associate Professor of Medicine
  • Lombardi Cancer Center
  • MedStar Georgetown University
  • Washington, DC

David Dingli, MD, PhD

  • Professor of Medicine
  • Division of Hematology
  • Mayo Clinic College of Science and Medicine
  • Rochester, Minnesota

Deva Sharma, MD, MS

  • Assistant Professor of Pathology, Microbiology, and Immunology
  • Vanderbilt University Medical Cener
  • Nashville, TN

Peter Martin, MD

  • Associate Professor of Medicine
  • Department of Medicine, Division of Hematology-Oncology
  • Weill Cornell Medical College
  • New York, New York

Sonali Smith, MD, FASCO

  • Elwood V. Jensen Professor of Medicine
  • Chief, Section of Hematology/Oncology
  • Co-Leader, Cancer Service Line
  • The University of Chicago
  • Chicago, Illinois

Julie Vose, MD

  • Neumann M. and Mildred E. Harris Professor
  • Chief, Section of Hematology/Oncology
  • Professor of Medicine
  • University of Nebraska Medical Center
  • Omaha, Nebraska



Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Physician Continuing Medical Education

Designation of Credit CCO designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

San Diego, CA

Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101

Not an official event of the 2023 ASH Annual Meeting and Exposition. Not sponsored, endorsed, or accredited by American Society of Hematology.


Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC.

For customer support please email:

Mailing Address Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from

Alexion Pharmaceuticals
Genentech, a member of the Roche Group
Ipsen Biopharmaceuticals, Inc.
Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Prothena Biosciences Limited
Regeneron Pharmaceuticals, Inc.